Neurobiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company Enter Into Binding Term Sheet for Worldwide License, Along With the Rights to Sublicense for All of Kds2010 Indications; Binding Term Sheet Includes Collaboration for Development and Commercialization of Novel Oral Tablet Kds2010 in Ongoing Phase 2 Cardiometabolic and Neurodegenerative Diseases
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.